Document is current
Any future updates will be listed below
-
Authors
Irvine, Edward B.
Nikolov, Angel
Khan, Mehak Z.
Peters, Joshua M.
Lu, Richard
Sixsmith, Jaimie
Wallace, Aaron
van Woudenbergh, Esther https://orcid.org/0000-0001-7363-6649
Shin, Sally
Karpinski, Wiktor
Hsiao, Jeff C. https://orcid.org/0000-0003-0800-9977
Casadevall, Arturo https://orcid.org/0000-0002-9402-9167
Bryson, Bryan D. https://orcid.org/0000-0003-1716-6712
Cavacini, Lisa https://orcid.org/0000-0003-1417-8339
Grace, Patricia S.
Alter, Galit https://orcid.org/0000-0002-7680-9215
Fortune, Sarah M. https://orcid.org/0000-0001-7565-9975
-
Funding
Funding for this research was provided by:
Bill and Melinda Gates Foundation (OPP1156795)
Bill and Melinda Gates Foundation (OPP1156795)
Foundation for the National Institutes of Health (75N93019C00071)
Foundation for the National Institutes of Health (AI150171-01)
Foundation for the National Institutes of Health (75N93019C00071)
Foundation for the National Institutes of Health (R01A1022553)
Foundation for the National Institutes of Health (U54CA225088)
Foundation for the National Institutes of Health (U2CCA233262)
Foundation for the National Institutes of Health (U2CCA233280)
Foundation for the National Institutes of Health (75N93019C00071)
- License Information
-
More Information
Article History
Received: 27 April 2022
Accepted: 9 July 2024
First Online: 22 August 2024
Competing interests
: G.A. is an employee of Moderna Therapeutics and holds equity in Leyden Labs and Seromyx Systems. M.Z.K. is an employee of Moderna Therapeutics. The other authors declare no competing interests.
